FindTrial
Sign In

To the study the role of vitamin D3 injection for treating cutaneous warts

Role of intralesional vitamin D3 injection in the treatment of cutaneous warts

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/013908
Enrollment
100
Registered
2018-05-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Vitamin D3: 0.2-0.5ml of intralesional vitamin D3 to be injected in warts depending on the size and number of warts(maximum 5 warts i.e. maximum 1ml of vitamin D3) per sitting for a max

Sponsors

Dr Shrini Parikh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 patients having cutaneous warts 2 patients > 18 years 3 patients with no prior treatment with either topical or destructive modalities for atleast 6 months

Exclusion criteria

Exclusion criteria: 1 patients 2 pregnant and lactating females 3 any evidence of immunosuppression including HIV 4 prior history of hypersensitivity to vitamin D3 5 previously diagnosed renal disease

Design outcomes

Primary

MeasureTime frame
regression of cutaneous wartsTimepoint: 2 weekly intervals for a maximum of 4 sessions—

Secondary

MeasureTime frame
to prevent recurrence of wartsTimepoint: for upto 6 months after resolution of warts—

Countries

India

Contacts

Public ContactDr Vivek Kumar Dey

Peoples college of medical sciences and reseach centre

drvivekdey@yahoo.co.in9981346039

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026